

## Suggested Reading

### *Progress in Prevention of IFIs & Promise of New Diagnostic Techniques*

#### PODCAST

Release Date: 5/21/2009 Expiration Date: 6/5/2010 Center Serial #: CV3103-1

1. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. *J Clin Oncol.* 2001;19(1):253-259.
2. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. *N Engl J Med.* 2007;356(4):348-359.
3. Forrest GN, Mankes K, Jabra-Rizk MA, et al. Peptide nucleic acid fluorescence in situ hybridization-based identification of *Candida albicans* and its impact on mortality and antifungal therapy costs. *J Clin Microbiol.* 2006;44(9):3381-3383.
4. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. *Clin Infect Dis.* 2006;43(1):25-31.
5. Lewis RE. What is the "therapeutic range" for voriconazole? *Clin Infect Dis.* 2008;46(2):212-214.
6. Meersseman W, Lagrou K, Maertens J, et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. *Am J Respir Crit Care Med.* 2008;177(1):27-34.
7. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. *Clin Infect Dis.* 2009;48(5):503-535.
8. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. *Clin Infect Dis.* 2008;46(3):327-360.